Zhijie Dai, Ronghua Zhu, Zhifeng Sheng, Guijun Qin, Xianghang Luo, Qun Qin, Chunli Song, Liping Li, Ping Jin, Guoping Yang, Yanxiang Cheng, Danhong Peng, Chong Zou, Lijuan Wang, Jianzhong Shentu, Qin Zhang, Zhe Zhang, Xiang Yan, Pingfei Fang, Qiangyong Yan, Lingfeng Yang, Xiao Fan, Wei Liu, Bo Wu, Rongrong Cui, Xiyu Wu, Yuting Xie, Chang Shu, Kai Shen, Wenhua Wei, Wei Lu, Hong Chen, Zhiguang Zhou
SHR-1222, a novel humanized monoclonal antibody targeting sclerostin, has been shown to induce bone formation and decrease bone resorption at a single dose ranging 50-400 mg in our previous phase 1 trial. This study was a randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial, which further investigated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of multiple ascending doses of SHR-1222 in women with postmenopausal osteoporosis (POP). A total of 105 women with POP were enrolled and randomly assigned...
2023: Frontiers in Endocrinology